References
Guidelines and research cited across this site.
Cited sources
- Goueli R, Badlani GH, Welliver C, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline (2026) part I: presentation and evaluation. J Urol. 2026;216(2):143-151. View source
- Goueli R, Badlani GH, Welliver C, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline (2026) part II: medical management. J Urol. 2026;216(2):152-160. View source
- Goueli R, Badlani GH, Welliver C, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline (2026) part III: procedural/surgical management. J Urol. 2026;216(2):161-170. View source
- Lin DW, Carlsson S, Filson CP, et al. Updates to early detection of prostate cancer: AUA/SUO guideline (2026). J Urol. 2026. View source
- Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol. 2023;210(1):46-53. View source
- Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part II: considerations for a prostate biopsy. J Urol. 2023;210(1):54-63. View source
- US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901-1913. View source
- Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol. 2013;190(6):2161-2167. View source
- McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195(5):1529-1537. View source
- McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-2398. View source
- Hashim H, Blanker MH, Drake MJ, et al. International Continence Society (ICS) report on the terminology for nocturia and nocturnal lower urinary tract function. Neurourol Urodyn. 2019;38(2):499-508. View source
- National Institute of Diabetes and Digestive and Kidney Diseases. Prostate Enlargement (Benign Prostatic Hyperplasia). Last reviewed June 2024. View source
- American Cancer Society. Key Statistics for Prostate Cancer. Last revised January 13, 2026. View source
- PROSCAR (finasteride) tablets, US prescribing information. Revised 03/2026. View source
- MedlinePlus, US National Library of Medicine. Tamsulosin: drug information. View source
- MedlinePlus, US National Library of Medicine. Finasteride: drug information. View source
Guideline links point to the publishing organization. Always check for the latest version.